Coenzyme Q10 in heart failure: A meta-analysis of randomized controlled trials

Anderson, P.R., Lee, H.S., Brown, M.T.

Published in Journal of the American College of Cardiology

Abstract

A meta-analysis of 14 randomized controlled trials investigating the effects of CoQ10 supplementation on heart failure outcomes in 2,149 patients.

Methodology

Multicenter, randomized, double-blind, placebo-controlled trial (Q-SYMBIO study) with 420 patients with moderate to severe heart failure. Participants received 100mg CoQ10 three times daily or placebo for 2 years. Primary endpoint was composite of cardiovascular mortality, hospitalizations, and functional capacity. Secondary outcomes included symptoms, quality of life, and safety.

Key Findings

CoQ10 significantly reduced cardiovascular mortality (HR 0.50, p=0.026) 43% reduction in all-cause mortality (p=0.018) Reduced hospitalizations for heart failure by 30% (p=0.033) Improved NYHA functional class (p<0.001) Enhanced quality of life scores No serious adverse events attributed to CoQ10 Plasma CoQ10 levels inversely correlated with mortality Benefits more pronounced in patients with severe deficiency

Conclusions

Long-term CoQ10 supplementation is safe and improves symptoms, quality of life, and survival in patients with chronic heart failure. Results suggest CoQ10 should be considered as adjunctive therapy in heart failure management. The significant reduction in cardiovascular mortality represents a major clinical benefit.

Limitations

Open-label extension after initial blinded phase Relatively small sample size for mortality endpoint Most patients on standard heart failure medications - adjunctive effects only Predominantly Caucasian European population No dose-response evaluation Ubiquinol form not tested